Jerry McMahon
Company: STORM Therapeutics Ltd.
Job title: Chief Executive Officer & President
Bio:
Jerry has over 30 years of biotechnology leadership, scientific innovation, creative deal-making, and financing experience. With broad disease-area expertise and a specialty in oncology therapeutics, Jerry has held scientific, pharmaceutical and venture capital positions and has been the CEO or President of multiple biotechnology companies leading novel therapeutic programs from discovery, development to drug approvals for internal and in-licensed products.
From 2016 to late 2021 Jerry was President and CEO of NASDAQ listed Harpoon Therapeutics building the Company from early stage through to IPO, follow-on financings, and development collaborations. Prior to that he held multiple positions, including President and CEO of Kolltan Pharmaceuticals which was acquired by Celldex, Innovative Medicine Head of Oncology and SVP at AstraZeneca-Medimmune and President at SUGEN/Pfizer where he was instrumental in invention and full development of several ground-breaking protein kinase inhibitors including sunitinib (Sutent®).
Jerry has also held academic appointments at the Yale Comprehensive Cancer Center at Yale University, Tufts University School of Medicine, and the Massachusetts Institute of Technology. He received his BS in biology and PhD in the field of biochemistry and genetics from Rensselaer Polytechnic Institute, has authored over 100 scientific and medical publications and is an inventor on over 60 US patents.
Seminars:
Panel Discussion: Building Strategic Collaborations & Investment Pathways to Accelerate RNA-Targeted Drug Discovery Across Biotech & Pharma 8:45 am
• Discussing the importance of pharma-biotech-academic collaborations and what each sector can provide to successfully create RNA-targeted therapeutics • How are large pharma and biotech companies structuring risk-sharing partnerships to access innovation and accelerate RNA-targeted therapeutic pipelines • How can early-stage companies leverage academic collaborations, tool compound sharing and co development deals to validate targets…Read more
day: Conference Day Two
Advancing the Therapeutic Potential of Epitranscriptomics: Storm’s Firstin- Class METTL3 Inhibitor, STC-15 9:45 am
• Preclinical data demonstrates that modulating RNA methylation via METTL3 inhibition can enhance tumor sensitivity to treatment and impair resistance mechanisms • Epitranscriptomic regulation produces durable changes to gene expression and the tumor microenvironment, suggesting anti-cancer efficacy through multiple mechanisms • STC-15 clinical and translational data point to broad utility of METTL3 inhibition, enabling new…Read more
day: Conference Day Two